Advanced Radiological Image Analysis for Cancers

Image Texture Analysis in assessing tumour heterogeneity: A tool to predict, prognosticate cancers and individualize radiation therapy.

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

CTRI

Registry ID

CTRI/2016/11/007484

Enrollment

400

Registered

2016-11-24

Start date

Unknown

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Brain tumours Lung Cancers Head and Neck cancers Lymphomas Health Condition 2: C329- Malignant neoplasm of larynx, unspecified

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: 1. patients with head and neck squamous cell cancers, lymphomas, brain tumors and lung cancers 2. The diagnostic imaging data sets of patients of above mentioned tumour types should be available. 3. All available baseline CT (with and without - contrast), various MRI sequences and PET scan will be used for texture analysis 4. Patient should sign the informed consent form

Exclusion criteria

Exclusion criteria: Patients who are unable to sign the informed consent form.

Design outcomes

Primary

Measure	Time frame
1.1 To asses heterogeneity exists in tumours of same species by image texture analysis. 1.2 To quantify the heterogeneity by image texture analysis Timepoint: NIL	—

Secondary

Measure	Time frame
Event free survival (EFS)Timepoint: 2 YEARS;Local control ratesTimepoint: 2 years;Overall SurvivalTimepoint: 2 years;Progression free survival (PFS) Timepoint: 2 years;Response RateTimepoint: 2 months to 6 months	—

Countries

India

Contacts

Public ContactDr Jai Prakash Agarwal

Tata Memorial Centre

agarwaljp@tmc.gov.in98672417770

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026